Selected article for: "abnormal dlco and lung function"
Author: Qin, Wei; Chen, Shi; Zhang, Yunxia; Dong, Fen; Zhang, Zhu; Hu, Bingzhu; Zhu, Ziyang; Li, Fajiu; Wang, Xiaojiang; Wang, Yimin; Zhen, Kaiyuan; Wang, Jing; Wan, YuLei; Li, Hongbo; Elalamy, Ismaïl; Li, Chenghong; Zhai, Zhenguo; Wang, Chen
Title: Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up
  • Cord-id: 3d5r5qwh
  • Document date: 2021_2_11
    • ID: 3d5r5qwh
    Snippet: OBJECTIVE: To evaluate pulmonary function and clinical symptoms in coronavirus disease 2019 (COVID-19) survivors within 3 months after hospital discharge, and to identify risk factors associated with impaired lung function. METHODS AND MATERIAL: COVID-19 patients were prospectively followed up with pulmonary function tests and clinical characteristics for 3 months following discharge from a hospital in Wuhan, China between January and February 2020. RESULTS: 647 patients were included. 87 (13%)
    Document: OBJECTIVE: To evaluate pulmonary function and clinical symptoms in coronavirus disease 2019 (COVID-19) survivors within 3 months after hospital discharge, and to identify risk factors associated with impaired lung function. METHODS AND MATERIAL: COVID-19 patients were prospectively followed up with pulmonary function tests and clinical characteristics for 3 months following discharge from a hospital in Wuhan, China between January and February 2020. RESULTS: 647 patients were included. 87 (13%) patients presented with weakness, 63 (10%) with palpitation and 56 (9%) with dyspnea. Prevalences of the three symptoms were markedly higher in severe patients than non-severe patients (19% versus 10% for weakness, p=0.003; 14% versus 7% for palpitation, p=0.007; 12% versus 7% for dyspnea, p=0.014). Results of multivariable regression showed an increased odd in the ongoing symptoms among severe patients (OR: 1.7, 95%CI: 1.1–2.6, p=0.026) or patients with longer hospital stay (OR: 1.03, 95%CI: 1.00–1.05, p=0.041). Pulmonary function test results were available for 81 patients, including 41 non-severe and 40 severe patients. In this subgroup, 44 (54%) patients manifested abnormal diffusion capacity for carbon monoxide (DLCO) (68% severe versus 42% non-severe patients, p=0.019). Chest CT total severity score (TSS)>10.5 (OR: 10.4; 95%CI: 2.5–44.1; p=0.001) on admission and ARDS (OR: 4.6; 95%CI: 1.4–15.5; p=0.014) were significantly associated with impaired DLCO. Pulmonary interstitial damage may be associated with abnormal DLCO. CONCLUSION: Pulmonary function, particularly DLCO, declined in COVID-19 survivors. This decrease was associated with TSS of chest CT >10.5 and ARDS occurrence. Pulmonary interstitial damage might contribute to the imparied DLCO.

    Search related documents:
    Co phrase search for related documents
    • aao diameter and acute respiratory syndrome: 1
    • aao diameter and acute respiratory syndrome patient: 1
    • abnormal dlco and acute respiratory: 1
    • abnormal dlco and acute respiratory syndrome: 1
    • abnormal lung function and acute respiratory: 1, 2, 3
    • abnormal lung function and acute respiratory syndrome: 1, 2, 3
    • abnormal lung function and acute respiratory syndrome patient: 1
    • abnormal pulmonary function and acute respiratory: 1
    • acute lung injury and admission scan: 1
    • acute lung injury and admission score: 1
    • acute respiratory and admission scan: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory and admission score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lobar involvement: 1, 2, 3
    • acute respiratory syndrome and admission scan: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and admission score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lobar involvement: 1, 2, 3
    • acute respiratory syndrome patient and admission score: 1
    • admission score and lobar involvement: 1